Manatt represented Vectura Group, a British pharmaceutical company focused on inhaled therapeutics, in its $11 million pre-merger convertible note financing with EnBiotix, a late-clinical stage rare disease biotechnology company focused on chronic respiratory disorders. Vectura Group led the investment with participation from the Cystic Fibrosis Foundation and Sanford Biosciences. The financing is expected to accelerate EnBiotix’s plans to deliver innovative products to cystic fibrosis and other rare disease patients with significant unmet needs, as well as further advance the development and commercialization of its inhaled drug portfolio.
The Manatt team was led by Corporate and Finance Partner Scott Schwartz. The team also included Venture Capital and Emerging Companies Partner Rustin Brown and Associate Darren Bartlette and Digital and Technology Associate Melanie DeFiore.
To learn more about the deal, click here.